
Ranolazine CAS NO.95635-55-5
We specialize in providing high-quality Ranolazine CAS NO.95635-55-5 for industrial clients across various sectors. Whether you need chemicals consultation, technical support, or detailed information about our production capabilities, our team is here to help.
Category:Active Pharmaceutical Ingredients MOQ:100KG Shipped directly from China
Introduction
Catalog ID80017137
CAS NO.95635-55-5
Purity 95%
MDL NumberMFCD00864690
EINEC Molecular Formula C24H33N3O4
Molecular Weight 427.5365
Aspect | Details |
---|---|
Mechanism of Action | Ranolazine is a late sodium channel blocker that inhibits the late sodium current (INa,late) in cardiac muscle cells. This action prevents calcium overload, reduces left ventricular wall tension, and increases coronary blood flow, leading to relief of angina. It also stabilizes the myocardial cell membrane, contributing to its anti-arrhythmic effects. |
Clinical Uses | Ranolazine is primarily used for the treatment of chronic stable angina. It is also being explored for its potential benefits in managing ischemic heart disease, particularly in patients with diabetes mellitus, and for preventing post-cardioversion and post-CABG atrial fibrillation. |
Dosage Forms | Available as extended-release tablets in doses of 500 mg and 1000 mg. Typical dosing is 500–1000 mg twice daily. |
Storage Conditions | Should be stored at room temperature, between 68°F to 77°F (20°C to 25°C), and can be exposed to temperatures between 59°F to 86°F (15°C to 30°C) for shorter periods. |
Side Effects | Common side effects include dizziness, headache, constipation, nausea, and fatigue. More serious adverse effects may include QT prolongation, renal impairment, and allergic reactions. |
Drug Interactions | Ranolazine is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and inducers (e.g., rifampin, St. John’s wort) can significantly alter ranolazine levels. Co-administration with metformin requires careful monitoring of blood glucose levels. |
Special Considerations | Caution is advised in patients with a history of long QT syndrome or renal impairment. Ranolazine is contraindicated in patients with hepatic cirrhosis and those allergic to the drug. |
Monitoring | Regular monitoring of the QT interval is recommended, especially when used with other QT-prolonging drugs. Patients should also be monitored for signs of renal impairment and neurologic adverse effects. |
Disclaimer: The above content is for reference and communication only among industry insiders, and does not guarantee its accuracy or completeness. According to relevant laws and regulations and the regulations of this website, units or individuals who purchase related items should obtain valid qualifications and qualification conditions.
If you're ready to take the next step or simply have a few questions, our experts are here to help. Connect with us today to learn more. ↓↓↓